EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

USP29 ‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Amelie S Schober, Leire Moreno-Cugnon, Laura Martínez-Pérez, Amaia Ercilla, Amaia Zabala-Letona, Adrián Vicente-Barrueco, Maider Fagoaga-Eugui, Saioa Garcia-Longarte iD, Blanca Calle-Ciborro, Encarnación Pérez-Andrés, Onintza Carlevaris, Sara Pozo und 5 weitere

Molecular Oncology · 2026-11 · 20 (11) · 2918-2935

DOI: 10.1002/1878-0261.70268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 13.05.2026. Verfasst von Amelie S Schober und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación Cooperativa en Biociencias CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Parque Tecnológico de Bizkaia-Ed.801A…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Hypoxia-Inducible Factor 1, alpha Subunit, Ubiquitin-Specific Proteases. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MICIU/AEI/10.13039/501100011033 and ESF+, MICIU/AEI/10.13039/501100011033, MICIU/AEI/10.13039/501100011033 and FEDER/EU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxygen availability is frequently compromised in solid tumours, making intratumoural hypoxia a common feature of cancer. In prostate cancer (PCa), hypoxia is strongly associated with aggressive disease and poor prognosis. Hypoxia‐inducible factor (HIF) is the master transcriptional regulator mediating hypoxia adaptation and is mainly controlled through proteasomal degradation of its α‐subunit by the ubiquitin–proteasome system (UPS). However, the contribution of deubiquitinases (DUBs) to HIF signalling in PCa remains largely unexplored. Using a computational strategy based on CA9 expression as a surrogate of HIF activity, we identified Ubiquitin‐Specific Protease 29 (USP29) as a key regulator associated with hypoxia and tumour progression and severity in PCa. Mechanistically, USP29 functions as a noncanonical positive regulator of HIF‐α stability in a catalytic‐dependent manner. USP29 interacts with HIF‐1α, reduces its poly‐ubiquitination and protects it from proteasomal degradation across multiple cancer cell lines. Additionally, USP29 stabilizes HIF‐2α acting on the C‐terminal region of HIF‐α. These findings uncover a novel regulatory layer of HIF signalling and highlight USP29 as a potential therapeutic target in hypoxia‐driven PCa progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHypoxia-Inducible Factor 1, alpha SubunitUbiquitin-Specific ProteasesHumansMaleProtein StabilityCell Line, TumorUbiquitinationProteasome Endopeptidase ComplexEndothelial PAS Domain-Containing Protein 1Cell HypoxiaAnimalsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

HIFUSP29deubiquitinaseshypoxiaprostate cancer

Substanzen

Hypoxia-Inducible Factor 1, alpha SubunitUbiquitin-Specific ProteasesProteasome Endopeptidase ComplexEndothelial PAS Domain-Containing Protein 1

Autor:innen und Institutionen

  • Centro de Investigación Cooperativa en Biociencias CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Parque Tecnológico de Bizkaia-Ed.801A, Derio, Spain.
  • Institute of Integrative Biology, Department of Biochemistry, Centre for Cell Imaging, University of Liverpool, UK.
  • Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Ikerbasque, Basque Foundation for Science, Bilbao, Bizkaia, Spain.
  • Translational Prostate Cancer Research Lab, CIC bioGUNE-Basurto, Biocruces Bizkaia Research Health Institute, Barakaldo, Spain.
  • Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.

ORCID-Profile: Saioa Garcia-Longarte, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Edurne Berra

Förderung

  • MICIU/AEI/10.13039/501100011033 and ESF+
  • MICIU/AEI/10.13039/501100011033
  • MICIU/AEI/10.13039/501100011033 and FEDER/EU

Zitieren

APA

Schober, A. S., Moreno-Cugnon, L., Martínez-Pérez, L., Ercilla, A., Zabala-Letona, A., Vicente-Barrueco, A., Fagoaga-Eugui, M., Garcia-Longarte, S., Calle-Ciborro, B., Pérez-Andrés, E., Carlevaris, O., Pozo, S., Mendizabal, I., Mayor, U., Carracedo, A., Sée, V., & Berra, E. (2026). USP29 ‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer. Molecular Oncology, 20(11), 2918-2935. https://doi.org/10.1002/1878-0261.70268

Vancouver

Schober AS, Moreno-Cugnon L, Martínez-Pérez L, Ercilla A, Zabala-Letona A, Vicente-Barrueco A, et al. USP29 ‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer. Molecular Oncology. 2026;20(11):2918-2935. doi:10.1002/1878-0261.70268

BibTeX
@article{Schober2026,
  author = {Schober, Amelie S and Moreno-Cugnon, Leire and Martínez-Pérez, Laura and Ercilla, Amaia and Zabala-Letona, Amaia and Vicente-Barrueco, Adrián and Fagoaga-Eugui, Maider and Garcia-Longarte, Saioa and Calle-Ciborro, Blanca and Pérez-Andrés, Encarnación and Carlevaris, Onintza and Pozo, Sara and Mendizabal, Isabel and Mayor, Ugo and Carracedo, Arkaitz and Sée, Violaine and Berra, Edurne},
  title = {USP29 ‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {11},
  pages = {2918--2935},
  doi = {10.1002/1878-0261.70268}
}
Kostenlos starten →